ClinicalTrials.gg
CompletedNCT03478969PRO SoloUpdated Aug 20, 2021Results posted

Participant-Reported Outcomes With the Accu-Chek® Solo Micropump System

An interventional study of Accu-Chek® Solo micropump system and mylife™ OmniPod® Insulin Management System in Diabetes Mellitus, Type 1, sponsored by Hoffmann-La Roche. Completed at 21 sites in 4 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-08-20.

Sponsored by Hoffmann-La Roche · Not applicable, Interventional, and Diagnostic

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
181
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies in Diabetes Mellitus, Type 1 by Hoffmann-La Roche — 1 open to participants now, 1 under way, none of them phase 3. Diabetes Mellitus, Type 1 · Hoffmann-La Roche.

Enrollment
4th of 15
181 · median 80
Started
2018
the only one that year
No phase
13 of 15
1 open now
Registered
12th of 15
by date

Among the 15 studies in Diabetes Mellitus, Type 1 by Hoffmann-La Roche, this one is the 4th largest by enrollment, is the only one that started in 2018, is one of 13 with no phase, and was the 12th registered.

Diabetes Mellitus, Type 1

3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

1 of the 15 studies in Diabetes Mellitus, Type 1 by Hoffmann-La Roche is open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 415 Diabetes Mellitus, Type 1 studies recruiting now, 129 (31%) set no upper age limit and 260 (63%) stop at 75 or younger; 187 take children under 18; 65 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Diabetes Mellitus, Type 1 by Hoffmann-La Roche, or all of them as a file.
02

Study summary

This interventional device study aims to compare mainly standard Multiple Daily Injection (MDI) therapy vs. Accu-Chek® Solo Micropump System and investigates participant satisfaction. In addition, a third arm is included to compare to only similar product on the market which is OmniPod. The third arm is for data collection purpose.

03

Conditions studied

  • Diabetes Mellitus, Type 1
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed type 1 diabetes mellitus
  • At least 6 months experience with MDI therapy
  • Age ≥18 years and age ≤ 65
  • Able to perform carbohydrate counting
  • Clinically suitable for CSII including willingness to measure blood glucose at least 4 times per day or to use flash or real-time continuous glucose monitoring consistently
  • between 7.5% (58 millimoles per mole (mmol/mol)) and 9.0% (75 mmol/mol) (determined within the last 2 months)
  • Ability and willingness to read and understand study materials (participant information, data protection and written consent form, all questionnaires etc.) and to comply with study procedures
  • Ability and willingness to use devices independently and respond to alarms after training and run-in phase
  • Using a blood glucose (BG)-meter or real-time continuous glucose monitoring device that can be downloaded via Accu-Chek® Smart Pix or willingness to use a compatible meter that will be provided for the duration of the study

Exclusion criteria

Exclusion Criteria:

  • Prior insulin pump use
  • Relevantly impaired hypoglycemia awareness
  • History of >1 hospitalization due to severe hypoglycemia within the previous 3 months
  • History of >1 hospitalization due diabetic ketoacidosis within the last 3 months
  • Significant manifestation of diabetes-related late complications
  • Pregnant or planning to become pregnant or breastfeeding
  • Known allergic reactions to plaster adhesive
  • Chronic use (therapy lasting for more than 3 months) of in adrenal suppressive doses, medication, or chemotherapy
  • Serious or unstable chronic medical or psychological condition(s)
  • Addiction to alcohol or other substance(s) of abuse as determined by the investigator
  • Psychological condition rendering the participant unable to understand the nature and the scope of the study
  • Plans for relocation or extensive travel
  • Participation in another clinical study within 4 weeks prior to the screening visit
  • Dependency on Sponsor or Investigator (e.g. co-worker or family member)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
181 participants (actual)

Study arms

  • Experimental
    Group A: Accu-Chek® Solo

    Continuous subcutaneous insulin infusion (CSII) with Accu-Chek® Solo Micropump system for 26 weeks. From Week 26 until Week 39, all Groups will be using the Accu-Chek® Solo Micropump system for CSII therapy.

    Device: Accu-Chek® Solo micropump system

  • Experimental
    Group B: MDI, then Accu-Chek® Solo

    Multiple daily injections (MDI) for 26 weeks. From Week 26 until Week 39, all Groups will be using the Accu-Chek® Solo Micropump system for CSII therapy.

    Device: Accu-Chek® Solo micropump system · Other: Multiple Daily Injections (MDI) therapy

  • Experimental
    Group C: mylife™ OmniPod®, then Accu-Chek® Solo

    Continuous subcutaneous insulin infusion (CSII) with the mylife™ OmniPod® Insulin Management system for 26 weeks. From Week 26 until Week 39, all Groups will be using the Accu-Chek® Solo Micropump system for CSII therapy.

    Device: Accu-Chek® Solo micropump system · Device: mylife™ OmniPod® Insulin Management System

Interventions

  • DeviceAccu-Chek® Solo micropump system

    Medical device for subcutaneous delivery of insulin in a personalized way.

  • Devicemylife™ OmniPod® Insulin Management System

    A patch pump system delivering insulin.

  • OtherMultiple Daily Injections (MDI) therapy

    Injecting insulin as per participant's need.

06

What researchers measure

Primary outcomes

  1. Treatment Satisfaction: Accu-Chek® Micropump System vs. MDI, Measured by the Difference in the Diabetes Technology Questionnaire (DTQ) Total Change Score

    The two comparisons will be performed using a hierarchical procedure. First, the comparison between the Accu-Chek® Solo system vs. MDI will be performed and only if the corresponding Null hypothesis of no difference between both systems can be rejected, then the second comparison between Accu-Chek® Solo system and versus mylife™ OmniPod® will also be performed. The DTQ questionnaire consists of 30 questions with the individual Change Scores ranging from 1 to 5, where 1 represents 'Much worse' and 5 represents 'Much better'. The Total Change Score Range on this questionnaire is from 30 to 150 with higher scores representing lower impairment and improved outcomes.

    Time frame: 26 weeks

  2. Treatment Satisfaction: Accu-Chek® Micropump System vs. Mylife™ OmniPod®, Measured by the Difference in the Diabetes Technology Questionnaire (DTQ) Total Change Score

    The two comparisons will be performed using a hierarchical procedure. First, the comparison between the Accu-Chek® Solo system vs. MDI will be performed and only if the corresponding Null hypothesis of no difference between both systems can be rejected, then the second comparison between Accu-Chek® Solo system and versus mylife™ OmniPod® will also be performed. The DTQ questionnaire consists of 30 questions with the individual Change Scores ranging from 1 to 5, where 1 represents 'Much worse' and 5 represents 'Much better'. The Total Change Score Range on this questionnaire is from 30 to 150 with higher scores representing lower impairment and improved outcomes.

    Time frame: 26 weeks

Secondary outcomes

  1. Diabetes-Related Emotional Distress Assessed by Problem Areas in Diabetes Scale (PAID)-5

    The PAID-5 questionnaire consisted of 5 questions with answers ranging from 0 (not a problem) to 4 (serious problem). The total score was calculated as the sum of the individual questions, resulting in a number between 0 and 20 where lower scores represented lower distress.

    Time frame: Week 26 up to Week 39

  2. Device Satisfaction and Treatment Preference

    Device Satisfaction and Treatment Preference was the main focus of part 2 questions of the DTQ. This part of the DTQ questionnaire consisted of individual sections with 9 questions each for the Blood Glucose Meter and Insulin Pump. Individual scores ranged from 1 (terrible) to 5 (excellent). Thus, the resulting sum score ranged from 9 to 45 for each type of device.

    Time frame: Baseline up to Week 39

  3. Therapy Success Confirmed by Glycated Hemoglobin (Hb1Ac) Levels

    Change in Glycated Haemoglobin (HbA1c) Levels from Baseline to Week 39

    Time frame: Baseline up to Week 39

  4. Therapy Success Indicated by Change in Body Mass Index (BMI)

    This outcome measure represents one reported value calculated by combining weight and height to report BMI in kg/m\^2. Change in BMI from Baseline to Week 39.

    Time frame: Baseline up to Week 39

  5. Therapy Success Indicated by Change in Weight

    Change in Weight from Baseline to Week 39

    Time frame: Baseline up to Week 39

  6. Change in Glycemic Index

    Change in Glycemic Index from Baseline to Week 39

    Time frame: Baseline up to Week 39

  7. Number of Participants With Therapy Parameters Indicated by Commencement of Continuous Subcutaneous Insulin Infusion (CSII)

    Continuous Subcutaneous Insulin Infusion (CSII) therapy is also referred to as Insulin Pump Therapy. Presented below, are the Number of Participants for whom certain indications e.g. HbA1c goals not met, resulted in commencement of CSII therapy.

    Time frame: Baseline up to Week 39

  8. Change in Therapy Parameters Based on Type of Insulin Used

    Time frame: Baseline up to Week 39

  9. Change in Therapy Parameters Indicated by Total Daily Insulin Dose (TDD)

    Total Daily Insulin Dose at Baseline compared to dose at Week 39

    Time frame: Baseline up to Week 39

  10. Change in Therapy Parameters Indicated by Total Daily Basal Insulin Dose (TBD)

    Total Daily Basal Insulin Dose at Baseline compared to dose at Week 39

    Time frame: Baseline up to Week 39

  11. Change in Therapy Parameters Based on Average Number of Self Monitoring of Blood Glucose (SMBGs) Per Day

    Average Number of Self Monitoring of Blood Glucose (SMBGs) per day from Baseline up to Week 39

    Time frame: Baseline up to Week 39

  12. Percentage of Time Spent in Hypoglycaemic Blood Glucose (BG) Ranges

    Change in Frequency of Hypoglycaemic Events are reported below as the percentage of time spent in hypoglycaemic blood glucose (BG) ranges.

    Time frame: Baseline up to Week 39

  13. Percentage of Time Spent in Hyperglycaemic Blood Glucose (BG) Ranges

    Change in Frequency of Hyperglycaemic Events are reported below as the percentage of time spent in hyperglycaemic blood glucose (BG) ranges.

    Time frame: Baseline up to Week 39

  14. Number of Consultations

    Consultations between scheduled visits, emergency and call center calls, hospitalizations and absenteeism from work/school.

    Time frame: Baseline up to Week 39

  15. Number of Pods/Infusion Assemblies Falling Off Prematurely

    Time frame: Baseline up to Week 39

  16. Average Time Spent on Infusion Assembly

    Time frame: Baseline up to Week 39

  17. Number of Participants With Skin Reactions (Including Type and Intensity)

    Number of Participants who experienced Skin Reactions at the Insulin Pump Insertion Sites (along with their Type and Intensity) are presented below, from Baseline up to Week 39. Participants were asked to assess five different properties describing potential problems at the pump insertion site, namely "itching", "redness", "swelling", "heat" and "pain". Each of these questions could be answered with one of four alternatives, "None", "Minor", "Moderate" and "Severe".

    Time frame: Baseline up to Week 39

  18. Socio-economic Acceptance: Amount of Insulin Left in Device at Reservoir Change/Device Discard

    Time frame: Baseline up to Week 39

  19. Amount of Waste, Inferred by Total Material Consumption

    Time frame: Baseline up to Week 39

07

Results

Posted Aug 16, 2021

Participant flow

The study was conducted at 21 centers in 4 countries.

Participant flow — Overall Study
MilestoneGroup A: Accu-Chek® SoloGroup B: MDI, Then Accu-Chek® SoloGroup C: Mylife™ OmniPod®, Then Accu-Chek® Solo
Started626158
Participants at end of parallel phase555852
Completed534940
Not completed91218
Withdrew: Withdrawal by subject476
Withdrew: Adverse event201
Withdrew: Pregnancy100
Withdrew: Personal reasons101
Withdrew: Covid-19143
Withdrew: Multiple reasons011
Withdrew: Eligibility criteria005
Withdrew: Lost to follow-up001

Outcome measures

PrimaryTreatment Satisfaction: Accu-Chek® Micropump System vs. MDI, Measured by the Difference in the Diabetes Technology Questionnaire (DTQ) Total Change Score

The two comparisons will be performed using a hierarchical procedure. First, the comparison between the Accu-Chek® Solo system vs. MDI will be performed and only if the corresponding Null hypothesis of no difference between both systems can be rejected, then the second comparison between Accu-Chek® Solo system and versus mylife™ OmniPod® will also be performed. The DTQ questionnaire consists of 30 questions with the individual Change Scores ranging from 1 to 5, where 1 represents 'Much worse' and 5 represents 'Much better'. The Total Change Score Range on this questionnaire is from 30 to 150 with higher scores representing lower impairment and improved outcomes.

Time frame:
26 weeks
Reported as:
Least squares mean · Scores on a Scale
Treatment Satisfaction: Accu-Chek® Micropump System vs. MDI, Measured by the Difference in the Diabetes Technology Questionnaire (DTQ) Total Change Score
Scores on a ScaleGroup A: Accu-Chek® SoloGroup B: MDI, Then Accu-Chek® Solo
Treatment Satisfaction: Accu-Chek® Micropump System vs. MDI, Measured by the Difference in the Diabetes Technology Questionnaire (DTQ) Total Change Score105.9 ± 2.6694.8 ± 2.63
PrimaryTreatment Satisfaction: Accu-Chek® Micropump System vs. Mylife™ OmniPod®, Measured by the Difference in the Diabetes Technology Questionnaire (DTQ) Total Change Score

The two comparisons will be performed using a hierarchical procedure. First, the comparison between the Accu-Chek® Solo system vs. MDI will be performed and only if the corresponding Null hypothesis of no difference between both systems can be rejected, then the second comparison between Accu-Chek® Solo system and versus mylife™ OmniPod® will also be performed. The DTQ questionnaire consists of 30 questions with the individual Change Scores ranging from 1 to 5, where 1 represents 'Much worse' and 5 represents 'Much better'. The Total Change Score Range on this questionnaire is from 30 to 150 with higher scores representing lower impairment and improved outcomes.

Time frame:
26 weeks
Reported as:
Least squares mean · Scores on a Scale
Treatment Satisfaction: Accu-Chek® Micropump System vs. Mylife™ OmniPod®, Measured by the Difference in the Diabetes Technology Questionnaire (DTQ) Total Change Score
Scores on a ScaleGroup A: Accu-Chek® SoloGroup C: Mylife™ OmniPod®, Then Accu-Chek® Solo
Treatment Satisfaction: Accu-Chek® Micropump System vs. Mylife™ OmniPod®, Measured by the Difference in the Diabetes Technology Questionnaire (DTQ) Total Change Score105.1 ± 3.04108.7 ± 2.85
SecondaryDiabetes-Related Emotional Distress Assessed by Problem Areas in Diabetes Scale (PAID)-5

The PAID-5 questionnaire consisted of 5 questions with answers ranging from 0 (not a problem) to 4 (serious problem). The total score was calculated as the sum of the individual questions, resulting in a number between 0 and 20 where lower scores represented lower distress.

Time frame:
Week 26 up to Week 39
Reported as:
Mean · Scores on a Scale
Diabetes-Related Emotional Distress Assessed by Problem Areas in Diabetes Scale (PAID)-5
Scores on a ScaleGroup A: Accu-Chek® SoloGroup B: MDI, Then Accu-Chek® SoloGroup C: Mylife™ OmniPod®, Then Accu-Chek® Solo
Week 267.0 ± 4.77.8 ± 4.35.3 ± 3.5
Week 396.3 ± 4.27.1 ± 4.55.8 ± 3.8
SecondaryDevice Satisfaction and Treatment Preference

Device Satisfaction and Treatment Preference was the main focus of part 2 questions of the DTQ. This part of the DTQ questionnaire consisted of individual sections with 9 questions each for the Blood Glucose Meter and Insulin Pump. Individual scores ranged from 1 (terrible) to 5 (excellent). Thus, the resulting sum score ranged from 9 to 45 for each type of device.

Time frame:
Baseline up to Week 39
Reported as:
Mean · Scores on a Scale
Device Satisfaction and Treatment Preference
Scores on a ScaleGroup A: Accu-Chek® SoloGroup B: MDI, Then Accu-Chek® SoloGroup C: Mylife™ OmniPod®, Then Accu-Chek® Solo
Screening (Blood Glucose Meter)35.3 ± 5.733.8 ± 5.435.7 ± 5.0
Week 13 (Blood Glucose Meter)34.9 ± 6.134.0 ± 5.634.9 ± 5.5
Week 26 (Blood Glucose Meter)34.3 ± 6.133.8 ± 5.134.9 ± 6.1
Week 39 (Blood Glucose Meter)34.7 ± 7.334.5 ± 5.834.8 ± 5.8
Week 13 (Insulin Pump)32.7 ± 7.3—35.3 ± 4.9
Week 26 (Insulin Pump)33.4 ± 6.6—35.3 ± 5.1
Week 39 (Insulin Pump)33.4 ± 6.933.8 ± 6.331.0 ± 7.0
SecondaryTherapy Success Confirmed by Glycated Hemoglobin (Hb1Ac) Levels

Change in Glycated Haemoglobin (HbA1c) Levels from Baseline to Week 39

Time frame:
Baseline up to Week 39
Reported as:
Mean · Percentage
Therapy Success Confirmed by Glycated Hemoglobin (Hb1Ac) Levels
PercentageGroup A: Accu-Chek® SoloGroup B: MDI, Then Accu-Chek® SoloGroup C: Mylife™ OmniPod®, Then Accu-Chek® Solo
HbA1c at Baseline8.0 ± 0.68.0 ± 0.58.0 ± 0.6
HbA1c after 13 weeks7.8 ± 0.88.0 ± 0.67.9 ± 0.9
HbA1c after 26 weeks7.9 ± 0.98.2 ± 0.77.9 ± 0.9
HbA1c after 39 weeks7.8 ± 0.98.2 ± 1.18.1 ± 0.9
SecondaryTherapy Success Indicated by Change in Body Mass Index (BMI)

This outcome measure represents one reported value calculated by combining weight and height to report BMI in kg/m\^2. Change in BMI from Baseline to Week 39.

Time frame:
Baseline up to Week 39
Reported as:
Mean · kg/m^2
Therapy Success Indicated by Change in Body Mass Index (BMI)
kg/m^2Group A: Accu-Chek® SoloGroup B: MDI, Then Accu-Chek® SoloGroup C: Mylife™ OmniPod®, Then Accu-Chek® Solo
Baseline25.4 ± 3.527.1 ± 4.727.0 ± 5.2
Week 1325.3 ± 3.527.1 ± 4.727.0 ± 5.2
Week 2625.4 ± 3.527.3 ± 5.027.3 ± 5.0
Week 3925.7 ± 3.427.4 ± 5.027.3 ± 5.2
SecondaryTherapy Success Indicated by Change in Weight

Change in Weight from Baseline to Week 39

Time frame:
Baseline up to Week 39
Reported as:
Mean · kg
Therapy Success Indicated by Change in Weight
kgGroup A: Accu-Chek® SoloGroup B: MDI, Then Accu-Chek® SoloGroup C: Mylife™ OmniPod®, Then Accu-Chek® Solo
Baseline77.2 ± 14.181.7 ± 17.783.4 ± 18.1
Week 1377.6 ± 14.382.3 ± 18.083.8 ± 17.2
Week 2678.4 ± 14.982.2 ± 18.284.3 ± 17.4
Week 3978.8 ± 14.682.4 ± 18.281.8 ± 17.1
SecondaryChange in Glycemic Index

Change in Glycemic Index from Baseline to Week 39

Time frame:
Baseline up to Week 39
Reported as:
Mean · mg/dL
Change in Glycemic Index
mg/dLGroup A: Accu-Chek® SoloGroup B: MDI, Then Accu-Chek® SoloGroup C: Mylife™ OmniPod®, Then Accu-Chek® Solo
Baseline to Week 1377.0 ± 15.071.7 ± 15.668.1 ± 10.2
Week 13 to Week 2675.0 ± 21.670.2 ± 13.168.9 ± 10.0
Week 26 to Week 3975.0 ± 17.073.9 ± 15.277.1 ± 15.2
SecondaryNumber of Participants With Therapy Parameters Indicated by Commencement of Continuous Subcutaneous Insulin Infusion (CSII)

Continuous Subcutaneous Insulin Infusion (CSII) therapy is also referred to as Insulin Pump Therapy. Presented below, are the Number of Participants for whom certain indications e.g. HbA1c goals not met, resulted in commencement of CSII therapy.

Time frame:
Baseline up to Week 39
Reported as:
Number · Participants
Number of Participants With Therapy Parameters Indicated by Commencement of Continuous Subcutaneous Insulin Infusion (CSII)
ParticipantsGroup A: Accu-Chek® SoloGroup B: MDI, Then Accu-Chek® SoloGroup C: Mylife™ OmniPod®, Then Accu-Chek® Solo
HbA1c goals not met626156
Participant wish474532
Frequent hypoglycemia9913
Dawn phenomenon322
Glycemic variability132
Shift working101
SecondaryChange in Therapy Parameters Based on Type of Insulin Used
Time frame:
Baseline up to Week 39
Reported as:
Number · U/kg
Change in Therapy Parameters Based on Type of Insulin Used
U/kgGroup A: Accu-Chek® SoloGroup B: MDI, Then Accu-Chek® SoloGroup C: Mylife™ OmniPod®, Then Accu-Chek® Solo
Short Acting Insulin: Insulin aspart (Screening)373039
Short Acting Insulin: Insulin glulisine (Screening)292
Short Acting Insulin: Insulin lispro (Screening)212217
Short Acting Insulin: Regular human insulin (Screening)200
Long Acting Insulin: Insulatard (Screening)110
Long Acting Insulin: Insulin degludec (Screening)9913
Long Acting Insulin: Insulin detemir (Screening)101213
Long Acting Insulin: Insulin glargine (Screening)423832
Long Acting Insulin: Protaphane (Screening)010
Short Acting Insulin: Insulin aspart (Week 13)341132
Short Acting Insulin: Insulin glulisine (Week 13)250
Short Acting Insulin: Insulin lispro (Week 13)20920
Long Acting Insulin: Insulin degludec (Week 13)03—
Long Acting Insulin: Insulin detemir (Week 13)08—
Long Acting Insulin: Insulin glargine (Week 13)114—
Short Acting Insulin: Insulin aspart (Week 26)342032
Short Acting Insulin: Insulin glulisine (Week 26)270
Short Acting Insulin: Insulin lispro (Week 26)191620
Short Acting Insulin: NovoRapid (Week 26)010
Long Acting Insulin: Insulin degludec (Week 26)010—
Long Acting Insulin: Insulin detemir (Week 26)09—
Long Acting Insulin: Insulin glargine (Week 26)125—
Short Acting Insulin: Insulin aspart (Week 39)362732
Short Acting Insulin: Insulin glulisine (Week 39)280
Short Acting Insulin: Insulin lispro (Week 39)222221
Long Acting Insulin: Insulin degludec (Week 39)310
Long Acting Insulin: Insulin detemir (Week 39)132
Long Acting Insulin: Insulin glargine (Week 39)032
SecondaryChange in Therapy Parameters Indicated by Total Daily Insulin Dose (TDD)

Total Daily Insulin Dose at Baseline compared to dose at Week 39

Time frame:
Baseline up to Week 39
Reported as:
Mean · U/kg
Change in Therapy Parameters Indicated by Total Daily Insulin Dose (TDD)
U/kgGroup A: Accu-Chek® SoloGroup B: MDI, Then Accu-Chek® SoloGroup C: Mylife™ OmniPod®, Then Accu-Chek® Solo
Screening0.7 ± 0.20.6 ± 0.20.7 ± 0.2
Week 130.6 ± 0.20.6 ± 0.20.6 ± 0.2
Week 260.6 ± 0.20.6 ± 0.20.6 ± 0.2
Week 390.6 ± 0.20.6 ± 0.20.6 ± 0.2
SecondaryChange in Therapy Parameters Indicated by Total Daily Basal Insulin Dose (TBD)

Total Daily Basal Insulin Dose at Baseline compared to dose at Week 39

Time frame:
Baseline up to Week 39
Reported as:
Mean · U/kg
Change in Therapy Parameters Indicated by Total Daily Basal Insulin Dose (TBD)
U/kgGroup A: Accu-Chek® SoloGroup B: MDI, Then Accu-Chek® SoloGroup C: Mylife™ OmniPod®, Then Accu-Chek® Solo
Screening0.3 ± 0.10.3 ± 0.10.3 ± 0.1
Week 130.3 ± 0.10.3 ± 0.10.2 ± 0.1
Week 260.3 ± 0.10.3 ± 0.10.3 ± 0.1
Week 390.3 ± 0.10.3 ± 0.10.3 ± 0.1
SecondaryChange in Therapy Parameters Based on Average Number of Self Monitoring of Blood Glucose (SMBGs) Per Day

Average Number of Self Monitoring of Blood Glucose (SMBGs) per day from Baseline up to Week 39

Time frame:
Baseline up to Week 39
Reported as:
Mean · SMBGs per day
Change in Therapy Parameters Based on Average Number of Self Monitoring of Blood Glucose (SMBGs) Per Day
SMBGs per dayGroup A: Accu-Chek® SoloGroup B: MDI, Then Accu-Chek® SoloGroup C: Mylife™ OmniPod®, Then Accu-Chek® Solo
Change in Therapy Parameters Based on Average Number of Self Monitoring of Blood Glucose (SMBGs) Per Day3.2 ± 3.03.4 ± 3.82.5 ± 3.1
SecondaryPercentage of Time Spent in Hypoglycaemic Blood Glucose (BG) Ranges

Change in Frequency of Hypoglycaemic Events are reported below as the percentage of time spent in hypoglycaemic blood glucose (BG) ranges.

Time frame:
Baseline up to Week 39
Reported as:
Mean · Percentage of Time Spent
Percentage of Time Spent in Hypoglycaemic Blood Glucose (BG) Ranges
Percentage of Time SpentGroup A: Accu-Chek® SoloGroup B: MDI, Then Accu-Chek® SoloGroup C: Mylife™ OmniPod®, Then Accu-Chek® Solo
<54 mg/dL (Baseline to Week 13)3.0 ± 7.51.6 ± 2.11.1 ± 1.9
<54 mg/dL (Week 13 to Week 26)1.8 ± 3.51.6 ± 1.90.9 ± 2.1
<54 mg/dL (Week 26 to Week 39)1.7 ± 2.20.8 ± 1.11.1 ± 2.9
>=54 and <70 mg/dL (Baseline to Week 13)5.8 ± 6.54.5 ± 3.03.1 ± 5.6
>=54 and <70 mg/dL (Week 13 to Week 26)4.9 ± 6.24.2 ± 4.23.2 ± 4.5
>=54 and <70 mg/dL (Week 26 to Week 39)5.6 ± 5.53.0 ± 3.11.4 ± 2.0
<70 mg/dL (Baseline to Week 13)8.8 ± 9.46.1 ± 4.74.2 ± 6.2
<70 mg/dL (Week 13 to Week 26)6.7 ± 8.85.8 ± 5.14.1 ± 4.8
<70 mg/dL (Week 26 to Week 39)7.3 ± 6.83.8 ± 3.72.5 ± 3.5
SecondaryPercentage of Time Spent in Hyperglycaemic Blood Glucose (BG) Ranges

Change in Frequency of Hyperglycaemic Events are reported below as the percentage of time spent in hyperglycaemic blood glucose (BG) ranges.

Time frame:
Baseline up to Week 39
Reported as:
Mean · Percentage of Time Spent
Percentage of Time Spent in Hyperglycaemic Blood Glucose (BG) Ranges
Percentage of Time SpentGroup A: Accu-Chek® SoloGroup B: MDI, Then Accu-Chek® SoloGroup C: Mylife™ OmniPod®, Then Accu-Chek® Solo
>180 to <250 mg/dL (Baseline to Week 13)19.3 ± 11.025.9 ± 9.026.4 ± 11.4
>180 to <250 mg/dL (Week 13 to Week 26)19.3 ± 12.625.5 ± 7.925.4 ± 12.1
>180 to <250 mg/dL (Week 26 to Week 39)20.3 ± 8.921.6 ± 10.126.6 ± 10.5
>250 mg/dL (Baseline to Week 13)17.4 ± 10.419.5 ± 9.516.4 ± 12.4
>250 mg/dL (Week 13 to Week 26)15.6 ± 12.518.9 ± 8.121.0 ± 15.5
>250 mg/dL (Week 26 to Week 39)20.3 ± 19.326.8 ± 17.229.2 ± 16.7
SecondaryNumber of Consultations

Consultations between scheduled visits, emergency and call center calls, hospitalizations and absenteeism from work/school.

Time frame:
Baseline up to Week 39

No measurements were reported for this outcome.

SecondaryNumber of Pods/Infusion Assemblies Falling Off Prematurely
Time frame:
Baseline up to Week 39

No measurements were reported for this outcome.

SecondaryAverage Time Spent on Infusion Assembly
Time frame:
Baseline up to Week 39

No measurements were reported for this outcome.

SecondaryNumber of Participants With Skin Reactions (Including Type and Intensity)

Number of Participants who experienced Skin Reactions at the Insulin Pump Insertion Sites (along with their Type and Intensity) are presented below, from Baseline up to Week 39. Participants were asked to assess five different properties describing potential problems at the pump insertion site, namely "itching", "redness", "swelling", "heat" and "pain". Each of these questions could be answered with one of four alternatives, "None", "Minor", "Moderate" and "Severe".

Time frame:
Baseline up to Week 39
Reported as:
Number · Number of Participants
Number of Participants With Skin Reactions (Including Type and Intensity)
Number of ParticipantsGroup A: Accu-Chek® SoloGroup B: MDI, Then Accu-Chek® SoloGroup C: Mylife™ OmniPod®, Then Accu-Chek® Solo
Baseline (Itching) (Minor Intensity)211
Baseline (Itching) (Moderate Intensity)000
Baseline (Itching) (Severe Intensity)000
Week 13 (Itching) (Minor Intensity)404
Week 13 (Itching) (Moderate Intensity)201
Week 13 (Itching) (Severe Intensity)001
Week 26 (Itching) (Minor Intensity)622
Week 26 (Itching) (Moderate Intensity)005
Week 26 (Itching) (Severe Intensity)000
Week 39 (Itching) (Minor Intensity)583
Week 39 (Itching) (Moderate Intensity)033
Week 39 (Itching) (Severe Intensity)102
Baseline (Redness) (Minor Intensity)133
Baseline (Redness) (Moderate Intensity)000
Baseline (Redness) (Severe Intensity)000
Week 13 (Redness) (Minor Intensity)8411
Week 13 (Redness) (Moderate Intensity)205
Week 13 (Redness) (Severe Intensity)000
Week 26 (Redness) (Minor Intensity)1539
Week 26 (Redness) (Moderate Intensity)004
Week 26 (Redness) (Severe Intensity)000
Week 39 (Redness) (Minor Intensity)161110
Week 39 (Redness) (Moderate Intensity)166
Week 39 (Redness) (Severe Intensity)011
Baseline (Swelling) (Minor Intensity)100
Baseline (Swelling) (Moderate Intensity)100
Baseline (Swelling) (Severe Intensity)000
Week 13 (Swelling) (Minor Intensity)317
Week 13 (Swelling) (Moderate Intensity)203
Week 13 (Swelling) (Severe Intensity)000
Week 26 (Swelling) (Minor Intensity)503
Week 26 (Swelling) (Moderate Intensity)001
Week 26 (Swelling) (Severe Intensity)000
Week 39 (Swelling) (Minor Intensity)216
Week 39 (Swelling) (Moderate Intensity)042
Week 39 (Swelling) (Severe Intensity)000
Baseline (Heat) (Minor Intensity)000
Baseline (Heat) (Moderate Intensity)000
Baseline (Heat) (Severe Intensity)000
Week 13 (Heat) (Minor Intensity)103
Week 13 (Heat) (Moderate Intensity)110
Week 13 (Heat) (Severe Intensity)000
Week 26 (Heat) (Minor Intensity)001
Week 26 (Heat) (Moderate Intensity)001
Week 26 (Heat) (Severe Intensity)000
Week 39 (Heat) (Minor Intensity)111
Week 39 (Heat) (Moderate Intensity)010
Week 39 (Heat) (Severe Intensity)010
Baseline (Pain) (Minor Intensity)433
Baseline (Pain) (Moderate Intensity)002
Baseline (Pain) (Severe Intensity)000
Week 13 (Pain) (Minor Intensity)313
Week 13 (Pain) (Moderate Intensity)112
Week 13 (Pain) (Severe Intensity)100
Week 26 (Pain) (Minor Intensity)333
Week 26 (Pain) (Moderate Intensity)102
Week 26 (Pain) (Severe Intensity)000
Week 39 (Pain) (Minor Intensity)344
Week 39 (Pain) (Moderate Intensity)113
Week 39 (Pain) (Severe Intensity)020
SecondarySocio-economic Acceptance: Amount of Insulin Left in Device at Reservoir Change/Device Discard
Time frame:
Baseline up to Week 39

No measurements were reported for this outcome.

SecondaryAmount of Waste, Inferred by Total Material Consumption
Time frame:
Baseline up to Week 39

No measurements were reported for this outcome.

Adverse events

Collected over Baseline up until a maximum of 40 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group A: Accu-Chek® Solo (Parallel Phase)0/62 (0%)6/62 (9.7%)44/62 (71%)
Group B: MDI (Parallel Phase)0/61 (0%)1/61 (1.6%)35/61 (57.4%)
Group C: Mylife™ OmniPod® (Parallel Phase)0/58 (0%)5/58 (8.6%)35/58 (60.3%)
Group D: Groups A+B+C (Solo Phase)0/165 (0%)4/165 (2.4%)82/165 (49.7%)
Most frequent serious events
Showing 10 of 19
Most frequent serious events
EventGroup A: Accu-Chek® Solo (Parallel Phase)Group B: MDI (Parallel Phase)Group C: Mylife™ OmniPod® (Parallel Phase)Group D: Groups A+B+C (Solo Phase)
HypoglycaemiaMetabolism and nutrition disorders3/621/611/582/165
VomitingGastrointestinal disorders0/620/611/580/165
Anaphylactic shockImmune system disorders0/620/611/580/165
OsteomyelitisInfections and infestations0/620/611/580/165
Arthropod biteInjury, poisoning and procedural complications0/620/611/580/165
Lower limb fractureInjury, poisoning and procedural complications0/620/611/580/165
Tendon ruptureInjury, poisoning and procedural complications0/620/611/580/165
Diabetic KetosisMetabolism and nutrition disorders0/620/611/580/165
Hypertensive crisisVascular disorders0/620/611/580/165
AnaemiaBlood and lymphatic system disorders1/620/610/580/165
Most frequent other events
Most frequent other events
EventGroup A: Accu-Chek® Solo (Parallel Phase)Group B: MDI (Parallel Phase)Group C: Mylife™ OmniPod® (Parallel Phase)Group D: Groups A+B+C (Solo Phase)
HypoglycaemiaMetabolism and nutrition disorders32/6228/6122/5849/165
NasopharyngitisInfections and infestations5/627/619/5812/165
HyperglycaemiaMetabolism and nutrition disorders4/620/614/5821/165
Diabetic ketosisMetabolism and nutrition disorders3/620/610/580/165

Baseline characteristics

Age, Continuous
Age, Continuous(years)Group A: Accu-Chek® SoloGroup B: MDI, Then Accu-Chek® SoloGroup C: Mylife™ OmniPod®, Then Accu-Chek® SoloTotal
Mean38.1 ± 11.838.6 ± 10.840.6 ± 13.139.0 ± 11.9
Sex: Female, Male
Sex: Female, Male(Participants)Group A: Accu-Chek® SoloGroup B: MDI, Then Accu-Chek® SoloGroup C: Mylife™ OmniPod®, Then Accu-Chek® SoloTotal
Female29292179
Male333237102
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Group A: Accu-Chek® SoloGroup B: MDI, Then Accu-Chek® SoloGroup C: Mylife™ OmniPod®, Then Accu-Chek® SoloTotal
White596056175
Asian1113
Other2013
08

Study locations

21 sites
  • VIVIT Institut am LKH Felkirch
    Feldkirch, 6800, Austria
  • LKH Graz, Medizinische Universität Graz
    Graz, 8036, Austria
  • Medizinische Universität Innsbruck
    Innsbruck, 6020, Austria
  • Salzburger Landeskliniken - Universitätsklinikum Salzburg (SALK)
    Salzburg, 5020, Austria
  • Diakonissen & Wehrle Privatklinik GmbH, Standort Andräviertel
    Salzburg, 5026, Austria
  • Hietzing Hospital
    Vienna, 1130, Austria
  • Diabetes Klinik Bad Mergentheim GmbH
    Bad Mergentheim, 97980, Germany
  • InnoDiab Forschung GmbH
    Essen, 45136, Germany
  • Gemeinschaftspraxis im Altstadt-Carree
    Fulda, 36037, Germany
  • Gemeinschaftspraxis Drs Bieber Kraus Nolte Vortherms
    Lage, 32791, Germany
  • Diabeteszentrum am CKQ
    Quakenbrueck, 49610, Germany
  • Diabendo Praxiszentrum
    Rostock, 18057, Germany
  • Regionalne Centrum Diabetologii - Uniwersyteckie Centrum Kliniczne
    Gdansk, 80-952, Poland
  • Jagiellonian University
    Krakow, 31-501, Poland
  • Central Clinical Hospital of the MSWiA in Warsaw
    Warsaw, 02-507, Poland
  • Bournemouth Diabetes and Endocrine Centre
    Bournemouth, BH7 7DW, United Kingdom
  • Wolfson Diabetes & Endocrine Clinic
    Cambridge, CB2 0QQ, United Kingdom
  • Centre for Clinical Research and Innovation
    Darlington, DL3 6HX, United Kingdom
  • King's College London, Diabetes Research Group
    London, SE5 9RS, United Kingdom
  • Imperial College London, Diabetes, Endocrinology and Metabolism Division
    London, W12 0NN, United Kingdom
  • Manchester Royal Infirmary, University Hospital
    Manchester, M13 9WL, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2018 to primary completion in May 2020, 24 months.

Results were first posted in Aug 2021, 1 year 2 months after primary completion.

Of 105 industry-sponsored interventional studies with no phase under Diabetes Mellitus, Type 1, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 18. This study's 24 months is above that.

Counting every sponsor, half of 953 studies reached it within 18 months; a quarter within 9 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 13, 2018
First posted
Mar 27, 2018
StartActual
May 17, 2018
Primary completionActual
May 18, 2020
CompletionActual
May 18, 2020
Results first posted
Aug 16, 2021
Last update
Aug 20, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03478969
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Mar 27, 2018
Start date
May 17, 2018
Primary completion
May 18, 2020
Completion
May 18, 2020
Results posted
Aug 16, 2021
Last update
Aug 20, 2021

Study contacts

Iris Vesper
study director · Hoffmann-La Roche

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion